Latest glioblastoma multiforme Stories
LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
BETHESDA, Md., June 4, 2014 /PRNewswire/ -- Northwest Biotherapeutics, Inc.
ResearchMoz.us include new market research report "Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted
ResearchMoz includes new market research report "AntiHypertensive Market and Glioblastoma Multiforme (GBM) Markets to 2019" to its huge collection of research reports.
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual RetailInvestorConferences.com VANCOUVER, British Columbia and MENLO PARK,
Pre-specified MGMT and HLA Subgroup Analyses Show Potentially Clinically Meaningful Survival Advantages for ICT-107 Treated Patients LOS ANGELES, June 1, 2014 /PRNewswire/ -- ImmunoCellular
Single agent NKTR-102 exceeds primary endpoint with fifty-five percent of patients achieving six-week progression-free survival and fifteen percent of patients achieving partial response
VANCOUVER, British Columbia and MENLO PARK, Calif., May 31, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI)
- Results from Phase I study of investigational oncology compound ABT-414 in patients with recurrent or unresectable glioblastoma multiforme, an aggressive type of brain cancer NORTH CHICAGO,
Company Reported Positive Preliminary Responses in Phase I/II Trial Patients; Feuerstein Falsely Claims There Is No Positive Trial Information BETHESDA, Md., May
- A transitional zone between two communities containing the characteristic species of each.